1 Min Read
Jan 11 (Reuters) - Eli Lilly And Co
* Lilly and Merck expand immuno-oncology collaboration
* Eli Lilly and co - financial details of collaboration were not disclosed.
* Lilly is sponsor of Phase 1 study and enrollment is expected to begin mid-2017.
* Eli Lilly - expansion of collaboration with Merck to add new study of lartruvo with keytruda in patients with previously treated soft tissue sarcoma Source text for Eikon: Further company coverage: